NewAmsterdam Pharma Co N.V (NAMS) Retained Earnings: 2022-2025
Historic Retained Earnings for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to -$687.5 million.
- NewAmsterdam Pharma Co N.V's Retained Earnings fell 47.40% to -$687.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$687.5 million, marking a year-over-year decrease of 47.40%. This contributed to the annual value of -$558.6 million for FY2024, which is 76.22% down from last year.
- According to the latest figures from Q3 2025, NewAmsterdam Pharma Co N.V's Retained Earnings is -$687.5 million, which was down 11.70% from -$615.5 million recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma Co N.V's Retained Earnings registered a high of -$194,463 during Q2 2023, and its lowest value of -$687.5 million during Q3 2025.
- Its 3-year average for Retained Earnings is -$456.0 million, with a median of -$466.4 million in 2024.
- Data for NewAmsterdam Pharma Co N.V's Retained Earnings shows a maximum YoY crashed of 231,176.39% (in 2024) over the last 5 years.
- Quarterly analysis of 4 years shows NewAmsterdam Pharma Co N.V's Retained Earnings stood at -$140.0 million in 2022, then tumbled by 126.35% to -$317.0 million in 2023, then slumped by 76.22% to -$558.6 million in 2024, then crashed by 47.40% to -$687.5 million in 2025.
- Its Retained Earnings was -$687.5 million in Q3 2025, compared to -$615.5 million in Q2 2025 and -$598.1 million in Q1 2025.